BioCentury
ARTICLE | Company News

AZ's Bohen departing after cancer-focused tenure

January 15, 2019 10:52 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor.

Shortly after Bohen joined the pharma in August 2015, AstraZeneca reduced its core SG&A expenses to boost investment in oncology (see "AZ Cutting Costs, Boosting Oncology Investment")...